Cargando…
Bayes factors for superiority, non-inferiority, and equivalence designs
BACKGROUND: In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Typically, evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. A null...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441196/ https://www.ncbi.nlm.nih.gov/pubmed/30925900 http://dx.doi.org/10.1186/s12874-019-0699-7 |
_version_ | 1783407513775898624 |
---|---|
author | van Ravenzwaaij, Don Monden, Rei Tendeiro, Jorge N. Ioannidis, John P. A. |
author_facet | van Ravenzwaaij, Don Monden, Rei Tendeiro, Jorge N. Ioannidis, John P. A. |
author_sort | van Ravenzwaaij, Don |
collection | PubMed |
description | BACKGROUND: In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Typically, evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. A null hypothesis is assumed (null effect, inferior by a specific amount, inferior by a specific amount and superior by a specific amount, for superiority, non-inferiority, and equivalence respectively), after which the probabilities of obtaining data more extreme than those observed under these null hypotheses are quantified by p-values. Although ubiquitous in clinical testing, the null hypothesis significance test can lead to a number of difficulties in interpretation of the results of the statistical evidence. METHODS: We advocate quantifying evidence instead by means of Bayes factors and highlight how these can be calculated for different types of research design. RESULTS: We illustrate Bayes factors in practice with reanalyses of data from existing published studies. CONCLUSIONS: Bayes factors for superiority, non-inferiority, and equivalence designs allow for explicit quantification of evidence in favor of the null hypothesis. They also allow for interim testing without the need to employ explicit corrections for multiple testing. |
format | Online Article Text |
id | pubmed-6441196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64411962019-04-11 Bayes factors for superiority, non-inferiority, and equivalence designs van Ravenzwaaij, Don Monden, Rei Tendeiro, Jorge N. Ioannidis, John P. A. BMC Med Res Methodol Technical Advance BACKGROUND: In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Typically, evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. A null hypothesis is assumed (null effect, inferior by a specific amount, inferior by a specific amount and superior by a specific amount, for superiority, non-inferiority, and equivalence respectively), after which the probabilities of obtaining data more extreme than those observed under these null hypotheses are quantified by p-values. Although ubiquitous in clinical testing, the null hypothesis significance test can lead to a number of difficulties in interpretation of the results of the statistical evidence. METHODS: We advocate quantifying evidence instead by means of Bayes factors and highlight how these can be calculated for different types of research design. RESULTS: We illustrate Bayes factors in practice with reanalyses of data from existing published studies. CONCLUSIONS: Bayes factors for superiority, non-inferiority, and equivalence designs allow for explicit quantification of evidence in favor of the null hypothesis. They also allow for interim testing without the need to employ explicit corrections for multiple testing. BioMed Central 2019-03-29 /pmc/articles/PMC6441196/ /pubmed/30925900 http://dx.doi.org/10.1186/s12874-019-0699-7 Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Technical Advance van Ravenzwaaij, Don Monden, Rei Tendeiro, Jorge N. Ioannidis, John P. A. Bayes factors for superiority, non-inferiority, and equivalence designs |
title | Bayes factors for superiority, non-inferiority, and equivalence designs |
title_full | Bayes factors for superiority, non-inferiority, and equivalence designs |
title_fullStr | Bayes factors for superiority, non-inferiority, and equivalence designs |
title_full_unstemmed | Bayes factors for superiority, non-inferiority, and equivalence designs |
title_short | Bayes factors for superiority, non-inferiority, and equivalence designs |
title_sort | bayes factors for superiority, non-inferiority, and equivalence designs |
topic | Technical Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441196/ https://www.ncbi.nlm.nih.gov/pubmed/30925900 http://dx.doi.org/10.1186/s12874-019-0699-7 |
work_keys_str_mv | AT vanravenzwaaijdon bayesfactorsforsuperioritynoninferiorityandequivalencedesigns AT mondenrei bayesfactorsforsuperioritynoninferiorityandequivalencedesigns AT tendeirojorgen bayesfactorsforsuperioritynoninferiorityandequivalencedesigns AT ioannidisjohnpa bayesfactorsforsuperioritynoninferiorityandequivalencedesigns |